The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Few companies have attracted more attention this year than Nvidia. The chipmaker is on a roll thanks to the rapid rise of ...

Better-than-expected trial data means Summit's bispecific antibody could replace the blockbuster Keytruda as a standard of ...

Those following along with Summit Therapeutics Inc. (NASDAQ:SMMT) will no doubt be intrigued by the recent purchase of shares by Robert Duggan, Co-CEO & Executive Chairman of the company, who spent a ...

The clinical-stage drugmaker's cancer therapy candidate outperformed Keytruda, the world's top-selling cancer drug.

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $14 ...

Summit Therapeutics shares are trading higher by 5.1% Thursday morning. The company announced it raised $235 million in net ...